Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS

Apellis Pharmaceuticals (APLS) Stock Price & Analysis

400 Followers

APLS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$33.32 - $70.76
Previous Close$62.1
Volume1.57M
Average Volume (3M)1.64M
Market Cap
$7.11B
Enterprise Value$6.67B
Total Cash (Recent Filing)$551.80M
Total Debt (Recent Filing)$112.71M
Price to Earnings (P/E)-10.1
Beta0.82
May 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.13
Shares Outstanding110,575,547
10 Day Avg. Volume1,015,643
30 Day Avg. Volume1,635,969
Standard Deviation0.17
R-Squared0.14
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)19.96
Price to Sales (P/S)116.30
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-16.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue88.43
Enterprise Value/Gross Profit95.57
Enterprise Value/Ebitda-10.80
Forecast
Price Target Upside28.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

APLS FAQ

What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $33.32 and its highest was $70.75 in the past 12 months.
    What is Apellis Pharmaceuticals Inc’s market cap?
    Currently, no data Available
    When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
    Apellis Pharmaceuticals Inc’s upcoming earnings report date is May 03, 2023 which is in 41 days.
      How were Apellis Pharmaceuticals Inc’s earnings last quarter?
      Apellis Pharmaceuticals Inc released its earnings results on Feb 21, 2023. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$1.528 by $0.028.
        Is Apellis Pharmaceuticals Inc overvalued?
        According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Apellis Pharmaceuticals Inc pay dividends?
          Apellis Pharmaceuticals Inc does not currently pay dividends.
          What is Apellis Pharmaceuticals Inc’s EPS estimate?
          Apellis Pharmaceuticals Inc’s EPS estimate is -$1.47.
            How many shares outstanding does Apellis Pharmaceuticals Inc have?
            Apellis Pharmaceuticals Inc has 114,465,300 shares outstanding.
              What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
              Apellis Pharmaceuticals Inc reported an EPS of -$1.5 in its last earnings report, beating expectations of -$1.528. Following the earnings report the stock price went up 12.513%.
                Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
                Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Farallon Capital Management, L.L.C.. It holds Apellis Pharmaceuticals Inc’s shares valued at 23M.

                  ---

                  Apellis Pharmaceuticals Stock Smart Score

                  The Apellis Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Apellis Pharmaceuticals Inc

                  Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Legend Biotech
                  Halozyme
                  Karuna Therapeutics
                  Exact Sciences

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis